Global Dynamics and Implications of an HBV Model with Proliferating Infected Hepatocytes
Source abstract
Abstract
Chronic hepatitis B (HBV) infection is a major cause of human suffering, and a number of mathematical models have examined the within-host dynamics of the disease. Most previous models assumed that infected hepatocytes do not proliferate; however, the effect of HBV infection on hepatocyte proliferation is controversial, with conflicting data showing both induction and inhibition of proliferation. With a family of ordinary differential equation (ODE) models, we explored the dynamical impact of proliferation among HBV-infected hepatocytes. Here, we show that infected hepatocyte proliferation in this class of models generates a threshold that divides the dynamics into two categories. Sufficiently compromised proliferation in infected cells produces complex dynamics characterized by oscillating viral loads, whereas higher proliferation generates straightforward dynamics that always results in chronic infection, sometimes with liver failure. A global stability result of the liver failure state was included as it is unique to this class of models. Finally, the model analysis motivated a testable biological hypothesis: Healthy hepatocytes are present in chronic HBV infection if and only if the proliferation of infected hepatocytes is severely impaired.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Hepatitis B Virus Studies · Hepatitis C virus research · Mathematical and Theoretical Epidemiology and Ecology Models
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Natural Science, Hampshire College, Amherst, MA 01002, USA
School of Mathematical and Statistical Sciences, Arizona State University, Tempe, AZ 85281, USA
Department of Life Sciences, Scottsdale Community College, Scottsdale, AZ 85256, USA
Funding
NIH
References (58)
Show source-provided references
1. Arguin, P., Kozarsky, P., and Reed, C. (2007). CDC Health Information for International Travel 2008, Elsevier.
2. World Health Organization (2020). Heptatitis B Fact Sheet, World Health Organization.
3. Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs10.1016/j.jhep.2015.01.018 ↗
4. HBV-Induced Immune Imbalance in the Development of HCC10.3389/fimmu.2019.02048 ↗
5. Immunobiology and Pathogenesis of Viral Hepatitis10.1146/annurev.pathol.1.110304.100230 ↗
6. Pathogenesis of Chronic Viral Hepatitis: Differential Roles of T Cells and NK Cells10.1038/nm.3251 ↗
7. Pang, X., Li, X., Mo, Z., Huang, J., Deng, H., Lei, Z., Zheng, X., Feng, Z., Xie, D., and Gao, Z. (2018). IFI16 is Involved in HBV-Associated Acute-on-Chronic LIver Failure Inflammation. BMC Gastroenterol., 18.10.1186/s12876-018-0791-1 ↗
8. Molecular Biology of Hepatitis B Virus Infection10.1016/j.virol.2015.02.031 ↗
9. Rethinking the Pathogenesis of Hepatitis B Virus (HBV) Infection10.1002/jmv.24270 ↗
10. Natural variants of hepatitis B virus X protein have differential effects on the expression of cyclin-dependent kinase inhibitor p21 gene10.1093/nar/gkh553 ↗
11. Blocking of G1/S transition and cell death in the regenerating liver of hepatitis B virus X protein transgenic mice10.1016/j.bbrc.2005.12.089 ↗
12. Impairment of liver regeneration correlates with activated hepatic NKT cells in HBV transgenic mice10.1002/hep.21597 ↗
13. Paracrine in vivo inhibitory effects of hepatitis B virus X protein (HBx) on liver cell proliferation: An alternative mechanism of HBx-related pathogenesis10.1073/pnas.092657699 ↗
14. Premature cell cycle entry induced by hepatitis B virus regulatory HBx protein during compensatory liver regeneration10.1158/0008-5472.CAN-08-2695 ↗
15. Within-host mathematical models of hepatitis B virus infection: Past, present, and future10.1016/j.coisb.2019.10.003 ↗
16. Modeling the dynamics of hepatitis B infection, immunity, and drug therapy10.1111/imr.12686 ↗
17. Viral dynamics in hepatitis B virus infection10.1073/pnas.93.9.4398 ↗
18. Nowak, M., and May, R. (2000). Virus Dynamics, Oxford University Press.10.1093/oso/9780198504184.001.0001 ↗
19. Virus dynamics: A global analysis10.1137/S0036139902406905 ↗
20. Mathematical analysis of HIV-1 dynamics in vivo10.1137/S0036144598335107 ↗
21. Mathematical modeling of the adaptive immune responses in the early stage of the HBV infection
22. The role of cells refractory to productive infection in acute hepatitis B viral dynamics10.1073/pnas.0603626104 ↗
23. The effect of immune responses in viral infections: A mathematical model view
24. Modeling the adaptive immune response in HBV infection10.1007/s00285-010-0397-x ↗
25. Forde, J., Ciupe, S., Cintron-Arias, A., and Lenhart, S. (2016). Optimal control of drug therapy in a hepatitis B model. Appl. Sci., 6.10.3390/app6080219 ↗
26. Mathematical modeling of HBV with the antiviral therapy for the immunocompromised patients
27. Kim, H., Kwon, H., Jang, T., Lim, J., and Lee, H. (2012). Mathematical modeling of triphasic viral dynamics in patients with HBeAg-positive chronic hepatitis B showing response to 24-week clevudine therapy. PLoS ONE, 7.10.1371/journal.pone.0050377 ↗
28. Dynamics of hepatitis B virus infection10.1016/S1286-4579(02)01603-9 ↗
29. Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections10.1086/656528 ↗
30. Dynamics of a delay differential model of hepatitis B virus10.1080/17513750701769873 ↗
31. Mathematical Analysis of a Basic Virus Infection Model with Application to HBV Infection10.1216/RMJ-2008-38-5-1573 ↗
32. Mathematical analysis of a virus dynamics model with general incidence rate and cure rate10.1016/j.nonrwa.2011.12.015 ↗
33. Stability analysis of a virus dynamics model with general incidence rate and two delays
34. Kuang, Y., Nagy, J., and Eikenberry, S.E. (2018). Introduction to Mathematical Oncology, CRC Press.10.1201/9781315365404 ↗
35. The Dynamics of a Delay Model of HBV Infection with Logistic Hepatocyte Growth
36. Rich dynamics of a hepatitis B viral infection model with logistic hepatocyte growth10.1007/s00285-009-0278-3 ↗
37. Modeling the mechanisms of acute hepatitis B virus infection10.1016/j.jtbi.2007.02.017 ↗
38. Modeling complex decay profiles of hepatitis B virus during antiviral therapy10.1002/hep.22586 ↗
39. Analysis of hepatitis C virus infection models with hepatocyte homeostasis10.1137/080714579 ↗
40. Ciupe, S., and Hews, S. (2012). Mathematical models of e-antigen mediated immune tolerance and activation following prenatal HBV infection. PLoS ONE, 7.10.1371/journal.pone.0039591 ↗
41. Ciupe, S., Ribeiro, R., and Perelson, A. (2014). Antibody responses during hepatitis B viral infection. PLoS Comput. Biol., 10.10.1371/journal.pcbi.1003730 ↗
42. Goyal, A., Ribeiro, R., and Perelson, A. (2017). The role of infected cell proliferation in the clearance of acute HBV infection in humans HBV infection in humans. Viruses, 9.10.3390/v9110350 ↗
43. Rodriguez, A., Chung, M., and Ciupe, S. (2017). Understanding the complex patterns observed during hepatitis B virus therapy. Viruses, 9.10.3390/v9050117 ↗
44. Dynamics of hepatitis B virus infection: What causes viral clearance?10.1080/08898480.2011.564563 ↗
45. Modeling and analysis of a marine bacteriophage infection10.1016/S0025-5564(97)10015-3 ↗
46. Global analysis of the Michaelis–Menten-type ratio-dependent predator-prey system10.1007/s002850100079 ↗
47. A simple epidemic model with surprising dynamics10.3934/mbe.2005.2.133 ↗
48. Rich dynamics of a simple delay host-pathogen model of cell-to-cell infection for plant virus
49. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo10.1136/gutjnl-2016-312162 ↗
50. Clonal expansion of normal-appearing human hepatocytes during chronic hepatitis B virus infection10.1128/JVI.00833-10 ↗
51. Interferon treatment for hepatitis B10.1016/j.cld.2016.06.002 ↗
52. Lampertico, P., Aghemo, A., Vigano, M., and Colombo, M. (2009). HBV and HCV therapy. Viruses, 484–509.10.3390/v1030484 ↗
53. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy10.1128/CMR.00046-19 ↗
54. Use of current and new endpoints in the evaluation of experimental hepatitis B therapeutics10.1093/cid/cix129 ↗
55. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis10.1002/hep.28280 ↗
56. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during PEGylated interferon-alpha2a, lamivudine and combination therapy10.1177/135965350601100201 ↗
57. Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed10.1053/jhep.2001.28509 ↗
58. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy10.1002/hep.510290626 ↗